A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices
medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…
AI Summary: Researchers have identified HORMAD1, a normally reproductive‑cell gene, as a vulnerability in some triple‑negative breast cancers. Preclinical work suggests exploiting this target could guide patient selection and novel therapies, opening a promising — if early‑stage — route for a tumor type that desperately needs smarter options.
- HORMAD1: reproductive gene reveals vulnerability in triple‑negative breast cancer (3)
- New insights into why aggressive breast cancers grow and spread (3)
- OTHER: related cancer research and approvals outside this TNBC angle (5)
- All Other Stories
HORMAD1: reproductive gene reveals vulnerability in triple‑negative breast cancer
New insights into why aggressive breast cancers grow and spread
OTHER: related cancer research and approvals outside this TNBC angle
All Other Stories
Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision
Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…
AI Summary: GSK has licensed its investigational drug linerixibat to Alfasigma for $300 million upfront, transferring global rights as the therapy nears regulatory decisions for cholestatic liver itch. The deal accelerates Alfasigma’s rare-disease ambitions while allowing GSK to reposition its pipeline — a tidy corporate shuffle with real implications for patients with debilitating pruritus.
Roche’s big hope breast cancer drug fails in crucial first-line trial
Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...
AI Summary: Roche’s experimental breast cancer oral agent failed to meet its primary endpoint in a pivotal first‑line trial, dashing expectations that it would become a major new therapy. The negative readout forces a strategic rethink for the program and raises questions about near‑term prospects for what had been touted as a potential blockbuster.
Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia
oncodaily - Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, […]
AI Summary: A global phase 3 trial shows romiplostim markedly reduces chemotherapy‑induced thrombocytopenia, cutting severe low‑platelet events and helping patients stay on planned treatment schedules. The finding promises to lower bleeding risk and avoid dose delays, a relief for clinicians and patients alike — and for anyone tired of rescheduled infusions.
Grail names new CEO as Bob Ragusa retires
Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...
AI Summary: Grail announced a leadership transition as long‑time chief executive Bob Ragusa retires and hands operational control to current president Josh Ofman. The move marks a new chapter for the cancer‑screening company as stakeholders watch for strategic shifts and commentary about the company’s unusual corporate journey and future direction.
Ipsen pulls cancer drug Tazverik from market over safety risks
Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...
AI Summary: Ipsen has removed its EZH2 inhibitor Tazverik (tazemetostat) from the U.S. market after safety issues flagged by an independent monitoring review. The withdrawal forces clinicians to pivot to alternative therapies and triggers regulatory and clinical re‑examination of the drug’s benefit‑risk profile for patients previously depending on it.